文献库搜索 | GeneLibs

Ting(JW),Lan(TTB),Cheng(YC),Chen(YT),Sun(A... Nanotechnology 2026-03-20

...MoS₂ QDs, the DETA-functionalized MoS2QDs/PVP fibers exhibit an increase in the photoluminescence (PL) with an enhanceme...

Savio(KT),Mishra(A),Pandey(AK),Singh(SK),S... ACS Sens 2026-07-24

...MOS) arguably offer the best sensitivity for a wide range of VOCs, their poor selectivity limits their performance. Here...

Zhang(W),Qin(J),Luo(J),Xiong(Y),Yang(F),Li... Cancer Immunol Immunother 2026-03-11

...mOS) was 24.1 months, and median progression-free survival (mPFS) was 8.6 months. Most patients demonstrated improved im...

Monte(A),Magris(R),Nardello(F),Vigolo(N),N... Gait Posture 2026-06-00

...MOS) training protocol on the plantarflexor muscles in T2D patients. How do muscle-tendon mechanics and walking energeti...

Mancuso(K),Masci(S),Talarico(M),Vitale(A),... Eur J Haematol 2026-06-00

...mOS has not been reached (95% CI 13.5-NR) either in the total population or in subgroups. Notably, 11/17 patients receiv...

Hu(Y),Guo(J),Liu(D),Wei(J),Chen(G),Su(T),L... Transl Cancer Res 2026-02-28

Mass-forming (MF) type is the most common, accounting for 57.1-83.6% of intrahepatic cholangiocarcinoma (ICC), with a po...

Cerbone(L),Roviello(G),Calabrò(F),Taha(T),... Front Immunol None

...mOS) reached 36.7 months in cisplatin-eligible and 25.6 months in cisplatin-ineligible patients in the first-line settin...

Li(M),Xu(Y),Liang(X),Xia(Y),Wang(W),Zhang(... Foot Ankle Int 2026-04-00

...MOS 36-Item Short-Form Health Survey (SF-36) score, visual analog scale (VAS), and International Clubfoot Study Group (I...

Baldi(GG),Giani(C),Ljevar(S),Denu(RA),Napo... Eur J Cancer 2026-05-02

...mOS-2 of 5.2 and 19.2 months; gemcitabine-based regimens (n = 15) a 42% ORR, with mPFS-2 and mOS-2 of 3.7 and 7.8 months...

Li(C),Zhao(X),Li(J),Geng(X),Yu(K),Liu(Y),Z... Acta Biomater 2026-04-00

...MoS₂ NPs were incorporated into the network. This integration significantly enhanced the photothermal conversion efficie...